| 4 | CITADEL ADVISORS LLC | 466K | $4.0M | +22.1% | 4.988% | 0.00% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 343K | $3.0M | +2.0% | 3.672% | 0.00% |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 274K | $2.4M | 0.0% | 2.935% | 0.00% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 266K | $2.3M | +14.3% | 2.845% | 0.00% |
| 8 | Stonepine Capital Management, LLC | 246K | $2.1M | +10.6% | 2.626% | 0.54% |
| 9 | Alyeska Investment Group, L.P. | 204K | $1.8M | 0.0% | 2.180% | 0.00% |
| 10 | Schonfeld Strategic Advisors LLC | 196K | $1.7M | — | 2.091% | 0.01% |
| 11 | Carlyle Group Inc. | 184K | $1.6M | 0.0% | 1.971% | 0.02% |
| 12 | NEXTBio Capital Management LP | 158K | $1.4M | 0.0% | 1.688% | 0.63% |
| 13 | TWO SIGMA INVESTMENTS, LP | 97K | $837K | +124.6% | 1.036% | 0.00% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 96K | $827K | -5.4% | 1.023% | 0.00% |
| 15 | DAFNA Capital Management LLC | 94K | $811K | 0.0% | 1.004% | 0.15% |
| 16 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 86K | $743K | — | 0.919% | 0.01% |
| 17 | MARSHALL WACE, LLP | 79K | $687K | — | 0.850% | 0.00% |
| 18 | Trexquant Investment LP | 78K | $674K | +78.6% | 0.834% | 0.00% |
| 19 | JANE STREET GROUP, LLC | 71K | $610K | +90.3% | 0.755% | 0.00% |
| 20 | Burkehill Global Management, LP | 63K | $540K | 0.0% | 0.669% | 0.02% |
| 21 | BlackRock, Inc. | 62K | $537K | +69.8% | 0.665% | 0.00% |
| 22 | REGENERON PHARMACEUTICALS, INC. | 61K | $523K | 0.0% | 0.647% | 0.30% |
| 23 | Rangeley Capital, LLC | 51K | $440K | -9.1% | 0.544% | 0.40% |
| 24 | VANGUARD FIDUCIARY TRUST CO | 51K | $438K | +0.7% | 0.542% | 0.00% |
| 25 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 40K | $348K | -23.9% | 0.431% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ACET — a direct measure of their conviction.
| 57.58% |
| 142.41 pp |
| $40M |
| 91% |
| Q4 2024 | 64 | +3.2% | 199.99% | +139.72 pp | $452M | +474% |
| Q3 2024 | 62 | — | 60.27% | — | $79M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
12 institutions opened new positions in ACET during Q2 2026, while 7 fully exited. 40 added to existing positions and 4 trimmed.
ACET institutional ownership fell by 2.20 percentage points quarter-over-quarter, with a net change of +5 holders.
The top 10 institutions account for 72.8% of all reported 13F value in ACET, and the top 25 account for 93.9%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Adicet Bio, Inc. (ACET) Institutional Ownership